Japanese trading and pharmaceuticals company Kowa Co Ltd on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research. The company, which has been working with Tokyo's Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details. The original Reuters story misstated that ivermectin was "effective" against Omicron in Phase III clinical trials, which are conducted in humans.
Related Keywords
Japan , Japanese , , Kitasato University , Pharmaceuticals Company , Antiviral Effect , Micron , Kowa Co Ltd , Phase Iii Clinical Trials , Clinical Trials , Japanese Trading ,
vimarsana.com © 2020. All Rights Reserved.